Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Champions Oncology, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 22 | 25 | +3 |
| Shares | 5.78M | 5.72M | −64.9K (−1.1%) |
| Value | $28.2M | $49.0M | +$20.8M (+74.0%) |
New holders (6)
Institutions that held Champions Oncology, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 11,524 | $98.8K | 0.00% |
| Virtu Financial LLC | 11,051 | $95.0K | 0.01% |
| Citadel Advisors LLC | 10,868 | $93.1K | 0.00% |
| Advisor Group Holdings, Inc. | 100 | $857 | 0.00% |
| SBI Securities Co., Ltd. | 4 | $34 | 0.00% |
| Capital Advisors, Ltd. LLC | 48 | $0 | 0.00% |
Sold out (3)
Institutions that held Champions Oncology, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Goldman Sachs Group Inc | 48,413 | $235.8K |
| UBS Group AG | 1,279 | $6.23K |
| Simplex Trading, LLC | 113 | $0 |